Vasomedical
This article was originally published in The Gray Sheet
Executive Summary
Firm orchestrates a $3.5 mil. round of financing through the issuance of 5% Series C convertible preferred stock. Proceeds are tabbed to support expanded marketing initiatives aimed at increasing awareness among physicians, patients and insurers of the firm's EECP (enhanced external counterpulsation) non-invasive technology for treatment of angina pectoris in patients with coronary disease. Specific programs will include patient outreach initiatives and those aimed at demonstrating to HMOs the economic benefits of the device